Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Mar;34(2):74–78. doi: 10.1007/BF01741339

Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis

Emmanuel Katsanis 1,✉, Maria A Bausero 1, Augusto C Ochoa 2, Cynthia M Loeffler 3, Bruce R Blazar 1, Arnold S Leonard 3, Peter M Anderson 1
PMCID: PMC11038579  PMID: 1760819

Abstract

We investigated the in vivo effects of cyclophosphamide (CY) on interleukin-2(IL-2)-induced cytolytic function and spleen cell immunophenotype. Pretreatment of A/J mice with CY (25 mg/kg or 75 mg/kg) i.p. on days −10 and −15 followed by IL-2 (50 000 U i.p. on days 0 to +3) resulted in increased lysis of YAC-1 target cells compared to the group receiving IL-2 without previous CY therapy. In contrast, when CY was given on day -5, the cytotoxicity against YAC-1 was not enhanced. Phenotypic analysis of splenocytes obtained from mice treated with CY on day −10 or −15 revealed a relative decrease in L3T4- and Lyt2-positive T cells. In vivo depletion of natural killer (NK) cells by anti-asialoGM1, prior to IL-2 therapy, abrogated the enhancing effect of CY on cytolysis while in vivo elimination of T cells by anti-L3T4 and anti-Lyt2 monoclonal antibodies did not, indicating that in the absence of T cell antigenic challenge, the increased cytolytic function after CY administration is probably mediated through NK cells. These findings provide evidence that CY may be used more effectively in IL-2-based immunotherapy protocols, if consideration is given to timing of CY and IL-2 administration.

Key words: Cyclophosphamide; IL-2, NK activity; Cytolysis

Footnotes

Supported in part by the Children's Cancer Research Fund, the Concern II Foundation, RO1-CA-21 737, NO1-AI-85 002 and a contract to the University of Minnesota from OncoTherapeutics Inc. Dr. E. Katsanis is supported by a fellowship from the Medical Research Council of Canada. Dr. P. M. Anderson is supported by a Clinical Oncology Career Development Award from the American Cancer Society. This is paper no. 550 of the Immunobiology Research Center

References

  • 1.Abe F, Schneider M, Black PL, Talmadge JE. Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice. Cancer Immunol Immunother. 1989;29:231. doi: 10.1007/BF00199209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 1989;49:1649. [PubMed] [Google Scholar]
  • 3.Ballas ZK. Lymphokine-activated killer (LAK) cells: differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. J Immunol. 1986;137:2380. [PubMed] [Google Scholar]
  • 4.Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H. Augmentation of human immune response by cyclophosphamide. Cancer Res. 1982;42:4862. [PubMed] [Google Scholar]
  • 5.Berd D, Maguire HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986;46:2572. [PubMed] [Google Scholar]
  • 6.Eberlein TJ, Massaro A, Jung S, Rubinstein A, Burger U, Chang M, Schoof DD. Cyclophosphamide immunosuppression potentiates tumor infiltrating lymphocyte therapy in the mouse. Proc Am Assoc Cancer Res. 1989;30:371. [Google Scholar]
  • 7.Eggermont AMM, Sugarbaker PH. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumor model. Br J Cancer. 1988;58:410. doi: 10.1038/bjc.1988.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2-T cells. J Exp Med. 1985;161:1122. doi: 10.1084/jem.161.5.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Habu S, Fukui H, Shimamura M, Kasai M, et al. In vivo effects of anti-asialo-GM1: Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol. 1981;127:34. [PubMed] [Google Scholar]
  • 10.Hoover SK, Barrett SK, Turk TMT, Lee T, Bear HD. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol Immunother. 1990;31:121. doi: 10.1007/BF01742376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kasai M, Iwamori M, Nagai Y, et al. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol. 1980;10:175. doi: 10.1002/eji.1830100304. [DOI] [PubMed] [Google Scholar]
  • 12.Kedar E, Ben-Aziz R, Epstein E, Leshem B. Chemoimmunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. Cancer Immunol Immunother. 1989;29:74. doi: 10.1007/BF00199920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kim R, Lafreniere R, Borkenhagen K, Bryant LD. Induction of cytotoxicity from fresh splenocytes after in vivo administration in cyclophosphamide. Cancer Immunol Immunother. 1989;30:283. doi: 10.1007/BF01744895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lafreniere R, Borkenhage K, Bryant LD, Ng E. Enhancement of tumor infiltrating lymphocytes cytotoxicity by cyclophosphamide given systemically prior to tumor harvest. Proc Am Assoc Cancer Res. 1989;30:385. [PubMed] [Google Scholar]
  • 15.Markovic SN, Murasco DM. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of B16F10L murine melanoma. Cancer Res. 1991;51:1124. [PubMed] [Google Scholar]
  • 16.North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;55:1063. doi: 10.1084/jem.155.4.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA. Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 1988;48:122. [PubMed] [Google Scholar]
  • 18.Riccardi C, Barlozzari T, Santoni A, Herberman RB, Cesarini C. Transfer to cyclophosphamide-treated mice of natural killer (NK) cells and in vivo natural reactivity against tumors. J Immunol. 1981;126:1284. [PubMed] [Google Scholar]
  • 19.Rosenberg SA, Spiess P, Lafreniere R. A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;223:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 20.Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwatzentruber D, Wei JP, White DE. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  • 21.Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res. 1989;49:7086. [PubMed] [Google Scholar]
  • 22.Sahasrabudhe DM, de Kernion JB, Pontes JE, Ryan DM, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod. 1986;5:581. [PubMed] [Google Scholar]
  • 23.Silagi S, Schaefer AE. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide. J Biol Response Mod. 1986;5:411. [PubMed] [Google Scholar]
  • 24.Stockman GD, Heim LR, South MA, Trentin JJ. Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol. 1973;110:277. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES